Case Report: Omalizumab-Associated Hair Loss: A Case of Eyebrow Alopecia Areata, Literature Review and FAERS Database Analysis

This case report discusses a 52-year-old female with chronic spontaneous urticaria who developed eyebrow alopecia areata after 12 weeks of omalizumab treatment. Despite continuing omalizumab, topical tacrolimus was used, resulting in eyebrow regrowth by 28 weeks. A literature review and analysis of 756 cases from the FAERS database suggest that omalizumab may induce alopecia, particularly in females aged 18-60, though a direct cause-effect relationship is difficult to establish. Alopecia areata may be a rare and transient side effect of omalizumab, highlighting the need for clinician awareness and patient counseling.